|
|
|
|
|
|||||||
|
Session 71
Poster Session
IL-2 and Other Forms of Immunotherapy 4:30-6:30 pm 4E-F |
to view the poster for an abstract.| 514-M. | Long-Term Efficacy of Subcutaneous IL-2 Therapy in HIV Infection. Final Analysis of the ANRS 079 Randomized Trial and Long-Term Follow-up Y. Levy*1, C. Durier2, A. S. Lascaux1, C. Capitant2, C. Michon3, L. Weiss4, E. Oksenhendler5, J. A. Gastaut6, C. Goujard7, C. Rouzioux8, J. P. Aboulker2, J. F. Delfraissy7, and the ANRS 079 Study Group9 1Hosp. Henri Mondor, Créteil; 2INSERM, Villejuif; 3Hosp. Louis Mourier, Colombes; 4Hosp. Georges Pompidou, Paris; 5Hosp. Saint-Louis, Paris; 6Inst. Paoli-Calmettes, Marseille; 7Hosp. Bicêtre, Kremlin-Bicêtre; 8Hosp. Necker, Paris; and 9ANRS, Paris, France
| ||
| 515-M. | Long-Term Efficacy of Subcutaneous IL-2 Therapy in HIV Infection: Pro-Viral DNA in Patients of the ANRS 079 Trial M. Burgard*, C. Durier, C. Capitant, A. S. Lascaux, C. Michon, E. Netzer, C. Goujard, V. Foubert, J. P. Aboulker, J. F. Delfraissy, Y. Levy*, and C. Rouzioux for the ANRS 079 Study Group Paris, France
| ||
| 516-M. | Efficacy of Intermittent Subcutaneous Interleukin-2 (IL-2) in Antiviral-Experienced HIV-Infected Individuals with Detectable Viral Load: 3-Year Extended Follow-Up S. Nozza1, L. Magenta1, G. Poli2, G. P. Rizzardi3, A. Lazzarin1, and G. Tambussi*1 1Clin. of Infectious Diseases, San Raffaele; 2AIDS Immunopathogenesis Unit, IRCCS San Raffaele; and 3MOLMED, Milan, Italy
| ||
| 517-M. | Baseline Characteristics Associated with CD4+ Response after 3 Cycles of Subcutaneous (SC) Recombinant Human Interleukin-2 (IL-2) A. Labriola*1, E. Denning2, N. Klimas3, F. Gordin1, U.S. Dept. of Veterans Affairs Natl. Trial Coordinating Ctr., and the ESPRIT Study Group 1VA Med. Ctr. Washington, DC; 2Univ. of Minnesota, Minneapolis; and 3Miami VA Med. Ctr., FL
| ||
| 518-M. | Preliminary Analysis of the Safety and Immunologic Activity of Recombinant IL-2 in Children and Adolescents with HIV Infection L. V. Wood*, J. Zuckerman, S. Steinberg, D. Liewehr, E. DeCarlo, M. Beals, J. Wigginton, and the Pediatric HIV Working Group. 1NCI, NIH, Bethesda, MD
| ||
| 519-M. | Effect of Interleukine-2 (IL-2) on Hepatitis C Virus (HCV) in HIV-1/HCV Co-Infected Patients J. C. Lopez*, J. Cosin, P. Catalan, J. Berenguer, P. Miralles, B. Padilla, and M. Rivera Hosp. Gregorio Marañon, Madrid, Spain
| ||
| 520-M. | Emergence and Selection of Viral Immune Escape Following Antiretroviral Therapy and IL-2 Suspension in Primary and Chronic SIVmac251 Infection of Rhesus Macaques J. Nacsa*1, J. Stanton2 , Z. Hel1 , K. Kunstman2 , E. Tryniszewska1, 3, W-P. Tsai1 , L. Giuliani1 , J. Altman4 , D. I. Watkins5 , M. G. Lewis6 , P. Markham7 , D. F. Nixon8 , J. Tartaglia9 , K. A. Smith10 , S. Wolinsky2, and G. Franchini1 1NCI, NIH, Bethesda, MD; 2Northwestern Univ. Med. Sch., Chicago, IL; 3Med. Academy of Bialystok, Poland; 4Emory Univ. Vaccine Ctr. at Yerkes, Atlanta, GA; 5Wisconsin Regional Primate Res. Ctr., Madison; 6Southern Res. Inst., Frederick, MD; 7Advanced BioSci. Labs., Kensington, MD; 8Gladstone Inst. of Virology and Immunology and Univ. of California, San Francisco; 9Aventis-Pasteur, Toronto, ON, Canada; and 10Cornell Univ., New York, NY
| ||
| 521-M. | Phase I Study of Anti-LFA-1 Monoclonal Antibody (Cytolin) in Adults with HIV Infection D. Northfelt*1, A. Allen2, and P. Kapustay2 1Univ. of California, San Diego and 2Amerimmune Pharmaceuticals, Woodland Hills, CA
| ||
| 522-M. | Non-Specific Immunotherapy with Murabutide Significantly Improves Responses to Recall and to HIV-1 Antigens, in Patients Naïve to Antiretroviral Therapy. X. De La Tribonniere*1, 3, Y. Yazdanpanah1, Y. Mouton1, G. M. Bahr2, and 3 1Infectious Diseases, Tourcoing; 2Pasteur Inst., Lille; and 3ISTAC Biotech, Lille, France
| ||
| 523-M. | The Effects of GM-CSF on Plasma HIV-1 RNA and CD4 Lymphocyte Counts in HIV-1-Infected Subjects Receiving Concomitant Potent Antiretroviral Therapy J. Jacobson*1, M. Lederman2, J. Spritzler3, H. Valdez2, P. Tebas4, G. Skowron5, R. Wang3, J. B. Jackson6, L. Fox7, and M. Gilbert8 for the ACTG 5041 Team 1Mount Sinai Sch. of Med., New York, NY; 2Case Western Reserve Univ., Cleveland, OH; 3Harvard Univ., Boston, MA; 4Washington Univ. Sch. of Med., St. Louis, MO; 5Brown Univ., Providence, RI; 6Johns Hopkins Univ. Sch. of Med., Baltimore, MD; 7NIH, Bethesda, MD; and 8Immunex Corp., Seattle, WA
| ||
| 524-M. | Phenotypic and Functional Characterization of Dendritic Cells Generated from Monocytes of HIV-Infected Patients in the Presence of GM-CSF and Interferon- C. Carbonneil1, L. Weiss Laurence*1, and 2 1INSERM U430 Hosp. Broussais and 2Univ. Pierre et Marie Curie, Paris, France
| ||
| 525-M. | Long-Term Persistence and Safety of Gene-Modified Syngeneic CD4+ T Lymphocytes in HIV-Infected Patients A. Lu*1, J. Tavel1, B. Herpin1, V. Natarajan2, R. T. Davey1 , J. Kovacs3 , J. Falloon1 , M. A. Polis1, H. Masur3, and H. C. Lane1 1NIAID, NIH, Bethesda, MD; 2SAIC, Frederick, MD; and 3Clin. Ctr., NIH, Bethesda, MD
| ||
| 526-M. | Activation of an HIV-1 Reservoir during Hematopoietic Progenitor Cell Mobilization R. Rapaport*, D. Kuritzkes, R. T. Schooley, and T. B. Campbell Univ. of Colorado Hlth. Sci. Ctr., Denver
| ||
| 527-M. | Interleukin-2 (IL-2) Added to HAART in Primary HIV Infection Enhances Anti-HIV Immune Responses F. Hecht*1, J. Kahn1, B. Martinez-Marino1, M. Altfeld2, L. Liu1, McGrath1, R. Gascon1, M. Busch1,3, B. Walker 2, and J. Levy1 1Univ. of California, San Francisco; 2Harvard Univ., Boston, MA; and 3Blood Ctrs. of the Pacific, San Francisco, CA
| ||
| 527a-M. | Increases in Naïve CD4+ T Cells in IL-2-Treated HIV Patients is Primarily Due to Peripheral Expansion of Existing Naïve CD4+ T Cells V. Natarajan*1, R. A. Lempicki1, I. Sereti2, Y. Badralmma1, J. W. Adelsberger1, J. A. Metcalf2, R. Stevens1, M. W. Baseler1, J. A. Kovacs2, and H. C. Lane2 1SAIC, Frederick, MD and 2NIAID, NIH, Bethesda, MD
|
